Moleculin Biotech completes Part A enrollment in Phase 2/3 MIRACLE trial for relapsed or refractory AML
Bitget2026/09/29 12:45- Moleculin Biotech closed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML.
- No new results were presented; a comprehensive Part A data readout is planned for Q1 2027.
- Part A enrolled 89 patients, with the cohort expected to split roughly evenly between prior intensive chemotherapy and venetoclax-based regimens.
- The company expects the expanded dataset to clarify efficacy across these patient groups without changing the program’s timeline.
- Blinded trial data continue to show no cardiotoxicity signal, a key potential differentiator versus conventional anthracyclines.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
